Sleeve Gastrectomy Alters Exosomal miR-497-5p Cargo to Ameliorate Metabolic Dysfunction-Associated Steatotic Liver by Targeting GABARAPL1.

IF 3 3区 医学 Q3 ENDOCRINOLOGY & METABOLISM
Zenghui Li, Chenxu Tian, Mengqin Wang, Zhehong Li, Liang Wang, Zheng Wang, Chengyuan Yu, Dezhong Wang, Dongbo Lian, Nengwei Zhang
{"title":"Sleeve Gastrectomy Alters Exosomal miR-497-5p Cargo to Ameliorate Metabolic Dysfunction-Associated Steatotic Liver by Targeting GABARAPL1.","authors":"Zenghui Li, Chenxu Tian, Mengqin Wang, Zhehong Li, Liang Wang, Zheng Wang, Chengyuan Yu, Dezhong Wang, Dongbo Lian, Nengwei Zhang","doi":"10.2147/DMSO.S568182","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Obesity is strongly associated with metabolic dysfunction and steatotic liver disease (MASLD). Laparoscopic sleeve gastrectomy (LSG) effectively addresses severe obesity and its metabolic complications. Recent studies suggest that exosomes and their microRNA (miRNA) content mediate systemic metabolic improvements following bariatric surgery.</p><p><strong>Objective: </strong>This study aims to characterize plasma exosomal miRNAs before and after LSG, identify functional candidates linked to MASLD remission, and validate underlying mechanisms in vitro.</p><p><strong>Methods: </strong>Plasma exosomes from control subjects, as well as pre- and post-LSG patients, were isolated via ultracentrifugation, characterized, and subjected to high-throughput miRNA sequencing. Differential expression analysis, weighted gene co-expression network analysis, and random forest modeling were used to identify key miRNAs. Predicted targets, based on multi-database consensus, were integrated with paired liver transcriptomes from GEO (GSE106737, GSE83452). miRNA-target interactions were confirmed through dual-luciferase assays. In a free fatty acid-induced HepG2 MASLD model, miRNA mimics/inhibitors were employed to evaluate lipid accumulation (Oil Red O, intracellular triacylglycerol/total cholesterol) and target expression (qRT-PCR, Western blot).</p><p><strong>Results: </strong>LSG significantly altered circulating exosomal miRNA profiles. Six key miRNAs were identified, with miR-497-5p being the most prominent. Integrative analysis revealed GABARAPL1 as a direct target of miR-497-5p, and its upregulation in post-LSG liver tissues. Luciferase assays confirmed miR-497-5p binding to the GABARAPL1 3'UTR. In HepG2 cells, inhibition of miR-497-5p reduced lipid droplet formation and intracellular triacylglycerol/total cholesterol levels, while overexpression exacerbated steatosis. Inhibition also led to increased GABARAPL1 mRNA and protein levels.</p><p><strong>Conclusion: </strong>LSG induces significant remodeling of the circulating exosomal miRNA profile. Specifically, the downregulation of exosomal miR-497-5p post-LSG appears to alleviate hepatic lipid accumulation by derepressing its target, GABARAPL1, a key regulator of lipophagy. miR-497-5p is thus a potential biomarker and therapeutic target.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"19 ","pages":"568182"},"PeriodicalIF":3.0000,"publicationDate":"2026-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13075427/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DMSO.S568182","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Obesity is strongly associated with metabolic dysfunction and steatotic liver disease (MASLD). Laparoscopic sleeve gastrectomy (LSG) effectively addresses severe obesity and its metabolic complications. Recent studies suggest that exosomes and their microRNA (miRNA) content mediate systemic metabolic improvements following bariatric surgery.

Objective: This study aims to characterize plasma exosomal miRNAs before and after LSG, identify functional candidates linked to MASLD remission, and validate underlying mechanisms in vitro.

Methods: Plasma exosomes from control subjects, as well as pre- and post-LSG patients, were isolated via ultracentrifugation, characterized, and subjected to high-throughput miRNA sequencing. Differential expression analysis, weighted gene co-expression network analysis, and random forest modeling were used to identify key miRNAs. Predicted targets, based on multi-database consensus, were integrated with paired liver transcriptomes from GEO (GSE106737, GSE83452). miRNA-target interactions were confirmed through dual-luciferase assays. In a free fatty acid-induced HepG2 MASLD model, miRNA mimics/inhibitors were employed to evaluate lipid accumulation (Oil Red O, intracellular triacylglycerol/total cholesterol) and target expression (qRT-PCR, Western blot).

Results: LSG significantly altered circulating exosomal miRNA profiles. Six key miRNAs were identified, with miR-497-5p being the most prominent. Integrative analysis revealed GABARAPL1 as a direct target of miR-497-5p, and its upregulation in post-LSG liver tissues. Luciferase assays confirmed miR-497-5p binding to the GABARAPL1 3'UTR. In HepG2 cells, inhibition of miR-497-5p reduced lipid droplet formation and intracellular triacylglycerol/total cholesterol levels, while overexpression exacerbated steatosis. Inhibition also led to increased GABARAPL1 mRNA and protein levels.

Conclusion: LSG induces significant remodeling of the circulating exosomal miRNA profile. Specifically, the downregulation of exosomal miR-497-5p post-LSG appears to alleviate hepatic lipid accumulation by derepressing its target, GABARAPL1, a key regulator of lipophagy. miR-497-5p is thus a potential biomarker and therapeutic target.

套筒胃切除术通过靶向GABARAPL1改变外泌体miR-497-5p货物以改善代谢功能障碍相关的脂肪变性肝。
背景:肥胖与代谢功能障碍和脂肪变性肝病(MASLD)密切相关。腹腔镜袖胃切除术(LSG)有效地解决严重肥胖及其代谢并发症。最近的研究表明,外泌体及其microRNA (miRNA)含量介导了减肥手术后全身代谢的改善。目的:本研究旨在表征LSG前后血浆外泌体mirna,确定与MASLD缓解相关的功能候选物,并验证其体外机制。方法:通过超离心分离对照组以及lsg术前和术后患者的血浆外泌体,对其进行表征,并进行高通量miRNA测序。差异表达分析、加权基因共表达网络分析和随机森林模型用于鉴定关键mirna。基于多数据库共识的预测靶点与来自GEO (GSE106737, GSE83452)的配对肝转录组进行整合。通过双荧光素酶测定证实了mirna与靶标的相互作用。在游离脂肪酸诱导的HepG2 MASLD模型中,采用miRNA模拟物/抑制剂评估脂质积累(油红O,细胞内甘油三酯/总胆固醇)和靶表达(qRT-PCR, Western blot)。结果:LSG显著改变了循环外泌体miRNA谱。鉴定出6个关键mirna,其中miR-497-5p最为突出。综合分析显示GABARAPL1是miR-497-5p的直接靶点,其在lsg后肝组织中上调。荧光素酶测定证实miR-497-5p与GABARAPL1 3'UTR结合。在HepG2细胞中,抑制miR-497-5p可降低脂滴形成和细胞内甘油三酯/总胆固醇水平,而过表达则加重脂肪变性。抑制也导致GABARAPL1 mRNA和蛋白水平升高。结论:LSG诱导循环外泌体miRNA谱的显著重塑。具体来说,lsg后外泌体miR-497-5p的下调似乎通过抑制其靶标GABARAPL1来减轻肝脏脂质积累,GABARAPL1是脂质吞噬的关键调节因子。因此,miR-497-5p是一种潜在的生物标志物和治疗靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Pharmacology, Toxicology and Pharmaceutics-Pharmacology
CiteScore
5.90
自引率
6.10%
发文量
431
审稿时长
16 weeks
期刊介绍: An international, peer-reviewed, open access, online journal. The journal is committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert opinion and commentaries are all considered for publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书